Skip to content
Call Us Today! 1 (772) 595-9830 info@midwayresearch.com
FacebookTwitterLinkedInInstagram
Midway Research Center Logo Midway Research Center Logo Midway Research Center Logo
  • Home
  • About
  • Clinical Trials
    • Currently Enrolling Studies
    • Active, not recruiting Studies
    • What is a Clinical Trial?
    • Expectations
    • Studies Phases
    • Informed Consent
    • Closed Studies
  • Services
    • HIV
    • STD
    • HPV
    • Lipodystrophy
  • Journal Publications
  • Contact
  • Home
  • About
  • Clinical Trials
    • Currently Enrolling Studies
    • Active, not recruiting Studies
    • What is a Clinical Trial?
    • Expectations
    • Studies Phases
    • Informed Consent
    • Closed Studies
  • Services
    • HIV
    • STD
    • HPV
    • Lipodystrophy
  • Journal Publications
  • Contact

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

Home/Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults
Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adultsmidwayadmin2019-10-28T18:51:58+00:00

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

212355 (STAT) · Trial ·

Major Inclusion/Exclusion Criteria:

  1. HIV Treatment Naive 
  2. Diagnosed within 14 days prior to Screening
  3. No Hepatitis B infection

Read more

© Copyright 2012 -    |   AVADA THEME BY THEMEFUSION   |   ALL RIGHTS RESERVED   |   POWERED BY WORDPRESS
FacebookTwitterLinkedInInstagram